A deficiency of functional aspartylglucosaminidase (AGA) causes a lysosomal storage disease, aspartylglucosaminuria (AGU). The recessively inherited disease is enriched in the Finnish population, where 98% of AGU alleles contain one founder mutation, AGU Fin . Elsewhere in the world, we and others have described 18 different sporadic AGU mutations. Many of these are predicted to interfere with the complex intracellular maturation and processing of the AGA polypeptide. Proper initial folding of AGA in the endoplasmic reticulum (ER) is dependent on intramolecular disulfide bridge formation and dimerization of two precursor polypeptides. The subsequent activation of AGA occurs autocatalytically in the ER and the protein is transported via the Golgi to the lysosomal compartment using the mannose-6-phosphate receptor pathway. Here we use the three-dimensional structure of AGA to predict structural consequences of AGU mutations, including six novel mutations, and make an effort to characterize every known disease mutation by dissecting the effect of mutations on intracellular stability, maturation, transport and the activity of AGA. Most mutations are substitutions replacing the original amino acid with a bulkier residue. Mutations of the dimer interface prevent dimerization in the ER, whereas active site mutations not only destroy the activity but also affect maturation of the precursor. Depending on their effects on the AGA polypeptide the mutations can be categorized as mild, moderate or severe. These data contribute to the expanding body of knowledge pertaining to molecular pathogenesis of AGU.
INTRODUCTION
Mutations in genes encoding functional domains of human proteins result in human genetic diseases. Sickle-cell anemia was the first human genetic disorder providing evidence that a single amino acid change can dramatically alter the properties of a protein (1) . Since then, specific mutations of some 1100 human diseases have been identified; however, in only a fraction of these are consequences of mutations for the structure or cellular metabolism characterized in detail. The most common inherited disorder of glycoprotein catabolism is aspartylglucosaminuria (AGU; McKusick 208400). AGU results from the deficient activity of a lysosomal amidase, aspartylglucosaminidase [AGA, glycosylasparaginase, N 4 -(β-N-acetylglucosaminyl)-l-asparaginase, EC 3.5. 1.26] . This recessively inherited condition is manifested by excessive accumulation of uncleaved glygoasparagines, mainly aspartylglucosamine [2-acetamido-1-(β-l-aspartamido)-1,2-dideoxyglucose], in lysosomes as well as elevated metabolite levels in urine (2) . Patients exhibit a relatively uniform clinical phenotype characterized by progressive mental retardation from early childhood with minor connective tissue changes and premature death (3) . AGU is enriched in Finland: one mutation, denoted AGU Fin , represents 98% of the AGU alleles due to a founder effect (4) . Previously, altogether 20 different AGU alleles have been characterized and 18 of them represent sporadic AGU alleles found outside Finland (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) .
The synthesis of the functional AGA molecule is relatively complex. It is translated as a single precursor polypeptide chain of 346 amino acids (5) and the signal peptide is cleaved co-translationally in the endoplasmic reticulum (ER), where initial folding of the polypeptide occurs. Also in the ER, two precursor polypeptides dimerize (17) and the dimeric precursor complex is activated by an autocatalytic cleavage of the peptide bond between amino acids D205 and T206, resulting in a tetrameric molecule consisting of two α-and two β-subunits (18, 19) . The cleavage of the precursor into α-and β-subunits exposes the α-amino group of T206 necessary for the catalytic mechanism of AGA. The α-amino group of T206 in the Nterminus of the β-subunit acts as a base, which increases the nucleophilicity of the side-chain OH group (20) . In the Golgi, the glycosylation of the catalytically active molecule is completed and the lysosomal targeting signal, mannose-6-phosphate, is specifically added to the oligosaccharides of AGA, directing the mature hydrolase to the lysosomal compartment. The phosphorylation of AGA is dependent on three lysine residues and a tyrosine in spatially defined positions on the surface of the mature AGA molecule (21) . The three-dimensional structure of AGA is known based on X-ray crystallography. The details of the active site and the roles of individual amino acids for the catalytical activity are also known (20) . Two heterodimers both contain one α-and one β-subunit arranged into four layers; two central β-sheet layers are surrounded by α-helical layers, demonstrating that AGA is a member of the N-terminal nucleophile protein family (22, 23) .
The cell biological and biochemical characterization of mutated AGA polypeptides has included analyses of intracellular targeting and preliminary quantitative and qualitative analyses of polypeptides using immunoprecipitation and western blotting. However, detailed molecular characterization of the consequences of AGU mutations has not been performed in the majority of disease mutations. AGA represents a multimeric molecule which is functionally very sensitive to mutations. Firstly, the formation of the active molecule requires correct folding in the ER for the oligomerization and subsequent autocatalytic activation to take place (17) . Secondly, in the Golgi, the three-dimensional structure of the molecule determines whether phosphorylation and transport of AGA to lysosomes occurs or not (21) . Only if the AGA molecule is properly activated and transported to the lysosomes does the enzyme become functional in the correct subcellular location (24) .
Based on the three-dimensional structure of AGA we have here performed structural analyses of AGU mutations, including six novel mutations. We addressed the molecular pathogenesis of AGU by predicting the consequences of mutations for the three-dimensional structure of the AGA enzyme. Further, we expressed mutagenized polypeptides and monitored polypeptide stability, maturation, transport and enzymatic activity.
RESULTS

Identification of novel AGU mutations
To identify the molecular defect in AGU in altogether 10 uncharacterized patients originating from Italy, Pakistan, Finland or the United Kingdom, the patients' genomic DNA was amplified by PCR with intron-specific primers (11) . We determined the nucleotide sequences of each exon, exonintron boundaries and untranslated regions, and identified six previously unknown mutations. Two Italian compound heterozygote patients had the double mutation 34G→T + 1000G→T in one allele, which results in V12L and E334X at the protein level. In this family, we were unable to find disease-causing mutations in the other allele. Some DNA variants were found in introns but no further analysis of these was carried out due to a lack of patient cells. In two AGU families originating from Pakistan, the three patients were homozygous for the mutation 372_375del resulting in a frameshift and premature stopcodon, T125fsX126. One Finnish patient had a 755G→A mutation resulting in G252E in one allele, and the other allele contained the AGU Fin mutation. Interestingly, the 755G→A mutation is a de novo mutation, since the mutation was not found in the parents, whose parenthood was confirmed by genotyping with a 99.9% confidence level. The other Finnish patient had the AGU Fin mutant allele and the other allele contained the 770C→T mutation resulting in T257I. A British AGU patient had the 503G→A mutation in one allele resulting in W168X at the polypeptide level; on examining the other allele we were again unable to find disease-causing mutations in the exons, exon-intron boundaries, or in the 5′-or 3′-untranslated regions. Some intronic DNA variants were found but no further studies were carried out due to a lack of patient cells. Finally, two affected siblings from Italy were found to be homozygous for the mutation 754G→C leading to a G252R substitution in the AGA polypeptide. All the mutations were confirmed in the non-coding strand by sequencing. The novel mutations are listed in addition to previously published mutations in Table 1 and schematically presented in Figure 1 .
Some AGU mutations hit highly conserved amino acids
The nucleophile of AGA, T206, residing in the N-terminus of the β-subunit, is fully conserved across the species (Fig. 2) . Other active site residues show high conservation levels as well, but the lysosomal targeting residues, glycosylation sites, and disulfide bridge-forming residues (C64-69, C163-179, C286-306, C317-345) are conserved in mammals only. The positions of missense point mutations resulting in AGU affect amino acids with variable levels of conservation across the species (Table 2) . Three mutations hit residues in the active site, and three substitutions replace fully conserved residues whereas 12 substitutions change a less conserved residue. Figure 3 displays the location of AGU mutations in the threedimensional AGA structure.
Mutations commonly disturb the packing of the AGA molecule
In the light of three-dimensional information for the active AGA molecule, the mutations A42_A43insDA, G60D, S72P, G100E, A101V, C163S, G252E, G252R, T257I, G302R and C306R are located in a structural environment, which is insufficient to accommodate the replacing residue and thus disturb the correct packing of secondary structure elements. Figure 3 shows the locations of the point mutations at the polypeptide level and Figure 4 illustrates the detailed structural environment of the wild-type residues in the native AGA three-dimensional structure. Table 2 summarizes the mutation characterization data. In the case of the mutations R161Q+C163S and C306R the substitution of cysteine prevents the formation of a disulfide bridge in the initial folding of the AGA precursor polypeptide in the ER. G226 is located in the active site in a loop, which contains substrate-binding residues R234 and D237. Two mutations, A101V and F135S, reside on or near the interface between the two αβ-dimers of AGA and they were found to affect the dimerization of AGA. The replacement F135S introduces a hydrophilic residue in a hydrophobic environment in the dimer interface.
Mutant AGA polypeptides have defects in intracellular processing
We mutagenized AGA cDNA to create the new mutation constructs and expressed them as well as 16 previously published mutations. The effects of the mutations on the maturation of the AGA polypeptide were studied using the SVpoly expression vector and transient expression in COS-1 cells. Figure 5 shows the representative data of immunoprecipitation analysis of wild-type and mutant AGA polypeptides after a 6 h chase. We have reported earlier that the activation of precursor polypeptide occurs in less than 5 min after synthesis in the ER (18) . A 6 h chase allows the majority of the polypeptides to be processed if the molecules are folded sufficiently correctly (25) . We monitored the polypeptides after chase times of 1, 3 and 6 h. The relative amount of precursor polypeptide remained virtually unchanged for the majority of the mutations when 1 and 6 h chase polypeptides are compared, based on the quantitation using scanning of the radioactive signals on films (data not shown). The only exceptions were wild-type, V12L, F135S, G226D and T257I, for which the amount of precursor decreased from 1 to 6 h chase due to activation (wild-type, V12L and F135S) or abnormal processing (G226D and T257I). V12L, expressed separately from its concurrent mutation E334X, was the only mutant construct which showed normal processing of the precursor polypeptide, as well as active subunits, α and β, in amounts equal to wild-type AGA. In addition, the enzymatic activity was comparable to that in wild-type indicating that V12L is a polymorphism. F135S expressed minor amounts of normal Pro-α, α-and β-subunits and had some enzymatic activity. Normal sized precursor polypeptide was produced by the following constructs: A42_A43insDA, G60D, G100E, A101V, F135S, R161Q+C163S, G226D, G252E and T257I. Expression of G252R, P268fsX319, S269fsX274 and E334X produced truncated precursor polypeptides, whereas G314fsX378 produced an elongated AGA-polypeptide. Abnormal processing to α-and Pro-β-subunits was observed for S72P, G226D and T257I constructs. These mutant precursors were not processed into subunits in the ER but were transported to the lysosomes, where the trimming of the C-terminus of the α-subunit occurred producing the abnormal Pro-β-subunit. S72P exhibits an enzymatic activity of about 30% of wild-type due to extracellular autocatalytic activation of its precursor and subsequent endocytosis into cells (14) . The majority of mutations produced inactive polypeptides, which do not correspond to the sizes of normal AGA subunits. Table  3 lists the mutated AGA cDNA constructs expressed by us and by others, the corresponding AGA polypeptides produced in transient expression, and the enzymatic activity of the polypeptides. Out of 27 AGU mutations studied, all but V12L revealed problems in intracellular processing and 25 prevented the activation cleavage in the ER based on the data from 1, 3 and 6 h chase experiments. In the case of these 25 mutations the low activity obviously results from the lack of activation and cleavage of the AGA precursor into the α-and β-subunits.
Mutant AGA polypeptides are typically mistargeted
The intracellular distribution of AGA polypeptides was studied using the SVpoly mammalian expression vector in BHK cells. BHK cells were chosen for immunofluorescence analysis to reduce overexpression and protein synthesis was stopped for 3 h with cycloheximide to allow the proteins to be transported from the ER. In 3 h most AGA polypeptides reach the lysosomes if they are folded sufficiently correctly and a noticeable Table 1 . Nucleotide changes are presented above the exons. Corresponding changes in the polypeptide are presented below the bar representing the AGA precursor polypeptide. Substitutions are marked with a dot and deletions are marked with a triangle; the lines connecting the label to the exon illustrate the deleted region. Insertions are marked with two lines parting at the label end. The signal sequence (SS), in the N-terminus of the precursor polypeptide, is cleaved co-translationally in the ER from the AGA precursor polypeptide. Two precursors dimerize in the ER prior to activation. In the ER, the AGA precursor is autocatalytically cleaved between residues 205 and 206 revealing the amino group of T206, which is the nucleophile for the catalysis of glycoasparagine substrates. The α-and β-subunits of AGA comprise of amino acids 24-185 and 206-333, respectively. The areas represented by the gray boxes between subunits (residues 186-205) and at the C-terminus of β-subunit (residues 334-346) are cleaved off in lysosomes. The residue numbers of the cleaved peptides are deduced from the crystal structure. The products of normal AGA processing from precursor to active subunits are α and β, the abnormal processing resulting in α-and Pro-β-subunits, shown with amino acid numbers at the bottom. 1, 4 , concurrent mutations; 2,3 , compound heterozygote mutations; 5 , two different mRNA species in a patient.
signal should be visible outside the ER (14, 18) . After fixation the cells were stained with AGA-specific antibodies and co-stained with ER or lysosome-specific antibodies, and observed with confocal microscopy (Fig. 6) . Table 3 lists the results of immunofluorescence analysis. The V12L mutation is located in the signal sequence, but had no effect on transport. S72P polypeptides were visible in the ER, Golgi and lysosomes (14) . Similarly, in the case of F135S, G226D and T257I, part of the polypeptides remained in the ER while some lysosomal staining also occurred. The other missense mutations, excluding C306R, severely affected the initial folding since the AGA polypeptides remained in the ER. C306R and every mutation presenting an early stop-codon had even more severe consequences since no AGA polypeptides could be detected in the cells. Out of 27 AGU mutations studied, 22 demonstrated significant problems in the lysosomal targeting of AGA polypeptides.
DISCUSSION
We have made an effort here to characterize molecular consequences of AGU mutations at the polypeptide level. Besides analyzing the previously identified mutations, we also monitored the effect of six novel AGU mutations identified also noteworthy that no replacements of proline exist. Glycine and proline have specific roles in polypeptide structures: glycine enables tight turns of the polypeptide backbone and the small size of its side-chain fits in limited structural environments; on the other hand, proline reduces structural flexibility. The sequence of human AGA contains 31 glycine residues, half of which are close to active site amino acids. It has 17 proline residues, five of which are located very near the lysosomal targeting residues at the C-terminus of the α-subunit and provide rigidity to the polypeptide backbone. The mutation frequency of glycines emphasizes their significance to backbone flexibility at the sites where enzymatic catalysis and activation take place. In addition, glycines provide much of the required flexibility in the initial folding, which involves making and breaking of disulfide bonds by the ER resident enzyme, protein disulfide isomerase.
The mutations are grouped here according to the severity of the effect for the AGA polypeptide, based on intracellular maturation, lysosomal targeting or activity. They are considered to cause mild, moderate or severe effects. The clinical phenotype of AGU patients is reported to be relatively homogenous (24) . However, we don't have the clinical details of the progression or severity of symptoms for our patients, and thus we cannot at this point reliably analyze whether the severity of mutations at the polypeptide level is reflected in the clinical outcome.
Some AGU mutations alter the dimer interface disturbing the dimerization of precursors
P268fsX319, S269fsX274, G314fsX378 and E334X produced more stable polypeptides than C306R or L263X. This indicates that the amino acids in the α-helix BH1 and the following loop, which contains approximately D261-L267, might be important for polypeptide folding and stability. This hypothesis is supported by the AGA structure; these amino acids, similar to H124, are located between the αβ dimers of AGA and therefore might stabilize the interaction between two αβ dimers in the molecule. With H124 substitutions, the initial folding of precursors is defective, dimerization is prevented and the polypeptides face rapid degradation in the ER due to the important stabilizing role of H124 (19) . This is most probably true for amino acids D261-L267 as well. In addition, Riikonen et al. (17) have shown that the large loop structure consisting of the C-terminal part of the α-subunit is crucial for dimerization.
Mutations with mild effects
AGU mutations that produce intracellularly stable precursor polypeptides and at least a fraction of normal subunits are defined here as mild. Intracellularly, these AGA polypeptides are seen in the Golgi compartment and lysosomes in addition to the ER. The polypeptides may also have detectable enzyme activity.
The active site S72 stabilizes the α-amino group of the catalytic T206 with a hydrogen bond (20) . The loop structure in the active site funnel, which contains S72, is unable to accommodate the rigid proline residue without disturbing packing, and S72P substitution results in abnormal maturation (14) . A similar processing defect could be detected for the G226D mutation. G226 is located in the active site in a loop, which contains substrate binding residues R234 and D237. The tight backbone turn at G226 would be absent in the G226D substitution, since according to the Ramachandran plot such backbone torsion angles can only be allowed for glycine. The substitution might cause spatial problems and in any case the long side-chain of aspartic acid would occupy the active site preventing normal processing. Patients with the homozygous G226D mutation produce an additional mRNA species with exon 6 missing resulting in G208fsX210. This mRNA is prevalent and probably caused by a mis-splicing resulting from the alteration of an exonic splicing enhancer sequence (16) . The predicted Figure 3 . The three-dimensional structure of the native human AGA enzyme (1APY, Protein Data Bank, http://www.rcsb.org/pdb/). (Top) One half of the AGA molecule, comprising one α-and one β-subunit, is light blue and the other is dark blue. The locations of missense mutations and the insertion A42_A43insDA are yellow in the polypeptide backbone and the corresponding amino acid labels are adjacent to the residues. (Bottom) The molecule has been rotated along the X-axis. Three regions in both αβ dimers provide an abundance of contacts between the two αβ dimers of AGA: Firstly, the loop containing residue H124 is indicated by an arrow and label I. Secondly, the amino acids in the α-helix BH1 and the following loops are indicated by an arrow and label II, respectively. Thirdly, the large loop structure at the C-terminal end of the α-subunit is indicated by an arrow and label III.
effect of the G208fsX210 mutation would be severe because practically the whole β-subunit is deleted from the molecule (see later).
Naturally occurring active site mutations of AGA are rare. So far, the only mutations of residues directly involved in catalysis are the homozygous S72P and the novel heterozygous mutation T257I. T257 and G258 form the oxyanion hole that stabilizes a covalent enzyme-substrate transition state (20) . Isoleucine is unable to replace T257 in the catalytic reaction and an abnormal processing resembling that observed for S72P and G226D could be detected. Polypeptides with active site mutations R234A, R234Q, R234K and T257A (20) and several others substituting H204, D205 or T206 (19) were also processed abnormally. These mutations disrupt the autocatalytic activation of the AGA precursor in the ER by altering the threedimensional structure of the active site.
The consequences of the heterozygous F135S mutation are different from the other mild mutations. The structural environment of F135 is hydrophobic and the substitution of phenylalanine for hydrophilic serine most probably eliminates local stabilizing Van der Waals interactions. F135 makes hydrophobic contacts with T122 and L127, thus stabilizing the loop containing H124. H124 has been shown to be important for dimerization (19) . In addition, F135 has direct Van der A132fsX146 BG g F 1 3 5 S P P P P P P P 1 2
The spatial environment of mutations in native AGA crystal structure (1APY, Protein Data Bank). The native AGA amino acid residues that are substituted for by AGU mutations are marked with red labels next to the α-carbon atom. The small dots around these residues represent atomic contacts between neighboring residues; their Van der Waals surfaces are partially represented by the dots. The brighter the color of the dots, the smaller is the inter-atomic distance. Should the affected amino acid have side-chain-side-chain contacts with other amino acids, the labels of those residues are marked in white next to the α-carbon. A42 and A43 are located in an α-helix (A). The spatial environment around A43 is restricted; the side-chain of A43 has contacts to the side-chains of M209 and A56, and the main-chain atoms of A43 have contacts to other main-chain atoms. In the same manner, the spatial environment of native residues G60 (B), S72 (C), G100 (D), A101 (E), C163 (G), G252 (I), T257 (J),G302 (K) and C306 (L) is limited. F135 is located in a hydrophobic pocket and its side-chain has many contacts to neighboring side-chains (F), some of which are located in the other half of the native enzyme (indicated with an asterisk). The disulfide bridge between C163 and C179 is disrupted in the C163S patient mutation (G). G226 is located in a hydrophilic environment in the active site funnel of AGA (H); the nucleophile T206 is shown, although G226 and T206 have no direct contacts. The C306R mutation prevents the formation of the disulfide bridge between C306 and C286 (L).
Waals interactions with residues from the other half of the native enzyme. The delayed activation seen in biochemical experiments probably results from impaired dimerization in the ER, caused by the lack of stabilizing interactions between two precursor polypeptides. This results in low levels of the AGA subunits and decreased activity compared with wild-type AGA. The specific activity of F135S AGA was not studied.
Mutations with moderate effects
AGU mutations are classified here as moderate when they produce inactive precursor polypeptides, which remain unprocessed. These precursor polypeptides are retained in the ER and the majority of polypeptides face rapid degradation. The A42_A32insDA mutation adds two amino acids to the middle of an α-helix. The insertion most probably disturbs local folding in the ER, since the structural environment of A43 is restricted and the mutation changes the residue order of the helix. The consequences of the homozygous G60D mutation are very similar since the side-chain of aspartic acid is excessively bulky for local structure and results in misfolding of the polypeptide. Likewise, the substitution of valine for alanine at 101 disturbs the three-dimensional structure of AGA due to space limitations and probably also because the side-chain of A101 is in hydrophobic contact with the side-chain of L126. L126 resides in a loop containing H124, which provides crucial contacts between the two αβ dimers of AGA (19) . The most common AGU mutation worldwide is R161Q+C163S, designated the AGU Fin mutation. Ikonen et al. (26) have demonstrated that the causative C163S substitution is responsible for defective folding and premature degradation of the mutant AGA. Detailed molecular characterization shows that replacement of C163 with serine causes structural problems in addition to preventing the formation of the disulfide bridge between C163 and C179. This causes destabilization of the loop structure that provides contacts between the two αβ dimers of AGA. The main reason for the the mutated polypeptides to remain in the ER as monomeric precursor polypeptides is evidently that the initial folding is defective and dimerization is prevented (17) . C163 is also located very near to K177 and Y178, which form one of the three phosphotransferase recognition sites, and by interfering with phosphorylation the C163 substitution could block the lysosomal targeting (21) .
The unstable precursor molecules produced by the novel mutations G252E and G252R can be explained by the fact that according to the Ramachandran plot the backbone torsion angles at 252 are only allowed for glycine. G302R, a neighbor of the oxyanion hole residue T257, also made the precursor unstable.
Mutations with severe effects
AGU mutations resulting in remarkably unstable AGA polypeptide are defined here as severe. Trace amounts of mutant polypeptides in this category are seen after a 6 h chase, but they do not represent normal AGA precursor or subunits. AGA polypeptide is undetectable in immunofluorescence analysis of transfected cells even with AGA antibodies against the denatured subunits. These mutants are inactive and the polypeptides are severely shortened due to the premature stopcodons except in the case of C306R.
Peltola et al. (10) indicated that the early stop-codon in C64X faces partial readthrough during translation in the patients' fibroblasts. The patients' AGA mRNA was unstable, but traces of normal sized inactive precursor polypeptide were detected due to substitution of C64 with an unidentified amino acid. In transient expression the polypeptide was unstable. C64 forms a disulfide bridge with C69 that stabilizes the AGA molecule (17) . The lack of the stabilizing covalent bond leads to the formation of a dysfunctional gene product.
W34fsX45, I112fsX127, T123fsX142, T125fsX126 and A132fsX146 produce unstable polypeptides, as the novel mutation T125fsX126 demonstrates. Yet another mutation with a similar effect is a novel mutation, W168X, which was found in a British patient. The early stop-codon makes the Figure 5 . Representative data of the immunoprecipitation analysis of the wild-type and mutant AGA polypeptides after a 6 h chase. AGA polypeptides from COS-1 cells transfected with wild-type or mutant AGA-SVpoly were labelled and subsequently immunoprecipitated either in native form (WT, V12L, G226D, T257I) with antibody against the native enzyme, or in the denatured form (other mutations) with antibody against the denatured subunits of AGA. The polypeptides in the latter group were not visible if immunoprecipitated as in the former group. The polypeptides were resolved on 14% SDS-PAGE and observed with autoradiography. On both sides of the gel picture, the locations of the previously characterized AGA polypeptides are indicated. Normal AGA subunits, Pro-α, α, β, and β′, are marked with a dot. The abnormal Pro-β-subunit is pointed out with an arrow. +, mutations expressing active AGA. A42_A43insDA provides an example with two precursor polypeptides of slightly divergent size representing heterogeneous glycosylation of polypeptides. BG denotes the null-transfected COS-1 cell background expression as a control. 1 , concurrent mutations; 2 , compound heterozygote mutations.
AGA polypeptides completely unstable. Riikonen et al. (25) have demonstrated that even co-expression of both of the subunits from separate constructs is insufficient for the correct folding of the AGA molecule, and the resulting polypeptides are rapidly degraded. In these mutations the observation that the transfected cells contained no AGA polypeptides is logical since the mutated gene products lack the whole β-subunit and are therefore severely misfolded and rapidly degraded. Similarly, mutant polypeptides with L263X substitution were unstable although the polypeptides contain the correct active site amino acids. The lack of more than 80 β-subunit residues resulted in severe misfolding of the polypeptides and rapid degradation.
Replacement of the disulfide bond forming C306 with arginine results in total misfolding and rapid degradation of the synthesized polypeptides. The substitution disturbs the packing of the molecule. This is the determining factor in the misfolding, since C286S and C306S polypeptides were normally processed and active, demonstrating that the disulfide bridge between C306 and C286 is not crucial for the early folding and stability of AGA (17).
Conclusions
A rare disorder, AGU, provides a model for the characterization of the molecular details of a human disease. The results demonstrate that structural changes caused by missense mutations are the most common cause of the AGU disease. They cause folding problems and destabilization of AGA polypeptides by introducing bulky residues to limited spaces in threedimensional structure, affect active site residues, create electrostatic disturbances, or prevent disulfide bond formation. The predicted and observed consequences of AGA mutations are in good agreement. These data also indicate that three regions, a helix and a loop at the dimer interface and a large loop structure on the surface, provide crucial stabilizing interactions between two precursors in the ER. This molecular characterization of AGU mutations contributes to the expanding body of knowledge pertaining to human disease pathogenesis. After molecular characterization of the consequences of these mutations, details of AGA dimerization and activation are now better defined and a more comprehensive structure-function understanding of AGA is possible.
MATERIALS AND METHODS
Patients and sequencing analyses
DNA sample of one AGU patient was received from the United Kingdom and samples of two affected siblings were received from Italy. In addition, samples of two AGU families originating from Pakistan, samples of two families from Finland and samples of one family from Italy were obtained. Altogether the DNA of 10 new AGU patients was sequenced. The diagnosis was ascertained by the referring center on the basis of clinical findings, demonstration of urinary glycoasparagines and assay of AGA activity in cultured fibroblasts or peripheral blood leukocytes. In one Finnish family, with the patient carrying a de novo mutation, parenthood was confirmed with genotyping. The genotyping was performed with an AmpFLSTR Profiler PCR amplification kit according to instructions of the manufacturer (Applied Biosystems). PCR amplification of exons was performed with intron-specific primers (11) and sequencing of both strands of the AGA gene was performed with an ABI-Prism 377 DNA sequencer (Perkin Elmer). Sequencher software was used to analyze the data (Gene Codes).
In vitro mutagenesis
Mutagenesis was performed with a QuikChange or Chameleon site-directed mutagenesis kit (Stratagene) on an AGA cDNA template (26) . The gene was cloned into the BamHI site of the mammalian expression vector SVpoly containing the SV40 early promoter (27) . After this, the insert was sequenced to exclude the possibility of unwanted mutations.
Transfection, metabolic labelling and immunoprecipitation
COS-1 cells (CRL-1650; ATCC, Manassas) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and antibiotics. For transfection, the cells were seeded on 3 cm plates at a density of 3 × 10 5 cells per well. Transfection was performed with the FuGENE 6 transfection reagent (Roche) using 1.5 µg of the wild-type or mutant AGA cDNA construct per well. Following a 48 h incubation the cells were metabolically labelled for 1 h with [ 35 S]Cys (Amersham Pharmacia Biotech) followed by a 1, 3 or 6 h chase (28) . Immunoprecipitation was carried out with fixed Staphylococcus aureus cells (Calbiochem) (29) using AGA-specific polyclonal antibody against either the denatured AGA-subunits or the native enzyme (30) . The polypeptides were denatured by boiling them 5 min prior to the addition of antibodies against the denatured AGA subunits. The labelled polypeptides were separated by 14% SDS-PAGE under reducing conditions (31) and visualized by autoradiography.
Assay for AGA activity
The AGA activity measurement was performed subsequent to metabolic labelling. The modified assay (14) is based on colorimetric measurement of liberated N-acetylglucosamine (32) .
Immunofluorescence analysis and confocal microscopy
BHK-21 cells (CCL-10; ATCC, Manassas) were seeded on coverslips on 3 cm plates at a density of 5 × 10 4 cells per well, grown to 50-60% confluency and transfected like COS-1 cells. Following a 48 h incubation the cells were treated with 50 µg/ml cycloheximide (Sigma) for 3 h to stop protein synthesis. Thereafter, the cells were fixed with 4% paraformaldehyde, pH 7.5 for 30 min. The cells were permeabilized for 15 min with 0.2% saponin (Sigma) in phosphate-buffered saline containing 0.5% bovine serum albumin (Sigma), and thereafter incubated 45 min either with a 1:200 dilution of antibody against the denatured AGA-subunits or with a 1:600 dilution of rabbit polyclonal antibody against the native enzyme. ER was detected with a mouse antibody against protein disulfide isomerase (1:800; StressGen Biotechnologies), and lysosomes-late endosomes with a mouse antibody against LGP 120 (1:200; a gift from Jean Gruenberg, Department of Biochemistry, Geneva, Switzerland). The cells were co-stained with a 1:200 dilution of tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories) to localize AGA and with 1:200 dilution of fluorescein isothiocyanate (FITC)-conjugated goat antimouse IgG (Jackson ImmunoResearch Laboratories) to localize ER or lysosomes. Specimens were viewed with a 63× objective on a Leica DMR confocal immunofluorescence microscope (Leica) with TCS NT software.
